Inimex Pharmaceuticals

Advancing health by harnessing the body's natural defenses with innovative, non-inflammatory therapies.

Add To Watchlist
General Information
Company Name
Inimex Pharmaceuticals
Founded Year
2001
Location (Offices)
Founders / Decision Makers
Number of Employees
-
Industries
Biotechnology, Pharmaceutical
Funding Stage
Series B
Social Media

Inimex Pharmaceuticals - Company Profile

Inimex Pharmaceuticals is a clinical stage enterprise founded in 2001, dedicated to advancing health by harnessing the body's natural defenses with innovative, non-inflammatory therapies. The company specializes in the market introduction of Innate Defense Regulators (IDRs), pioneering drugs that activate the body's innate immune responses without inducing inflammation. In June 2008, the company received a significant $22.00M Series B investment from a consortium of investors including BDC Capital, Morningside Ventures, GrowthWorks Capital, Astellas Venture Management, BC Advantage Funds, Canadian Medical Discoveries Fund, Roche Venture Fund, and Discovery Capital. Inimex Pharmaceuticals operates within the industries of Biotechnology and Pharmaceuticals.

Taxonomy: biopharmaceuticals, clinical stage, innate immune response, drug development, immunotherapy, inflammation, immune system modulation

Funding Rounds & Investors of Inimex Pharmaceuticals (3)

View All
Funding Stage Amount No. Investors Investors Date
Series B $22.00M 8
GrowthWorks Capital, investor in Inimex Pharmaceuticals's Series B round Astellas Venture Management, investor in Inimex Pharmaceuticals's Series B round BC Advantage Funds, investor in Inimex Pharmaceuticals's Series B round Canadian Medical Discoveries Fund, investor in Inimex Pharmaceuticals's Series B round Roche Venture Fund, investor in Inimex Pharmaceuticals's Series B round Discovery Capital Management Corporation, investor in Inimex Pharmaceuticals's Series B round
BDC Venture Capital, Morningside Group 		02 Jun 2008
Series A $2.00M 2
Canadian Medical Discoveries Fund, investor in Inimex Pharmaceuticals's Series A round
British Columbia Discovery Fund 		08 Dec 2004
Series A $4.50M - 06 Jul 2004

Latest News of Inimex Pharmaceuticals

View All

No recent news or press coverage available for Inimex Pharmaceuticals.

Similar Companies to Inimex Pharmaceuticals

View All
Inflazome - Similar company to Inimex Pharmaceuticals
Inflazome Inflazome develops drugs to block inflammasome signals, reducing unwanted inflammation associated with diseases.
Q32 Bio Inc. - Similar company to Inimex Pharmaceuticals
Q32 Bio Inc. Revolutionizing the future of targeted immune therapeutics
PIN Pharma - Similar company to Inimex Pharmaceuticals
PIN Pharma A pioneering biopharmaceutical firm dedicated to creating broad-based immuno-modulatory therapies by synergizing the innate and adaptive immune systems.
Telormedix - Similar company to Inimex Pharmaceuticals
Telormedix Pioneering targeted immunity for cancer and autoimmune disease treatment through innovative biopharma solutions
Innate Pharma - Similar company to Inimex Pharmaceuticals
Innate Pharma
Circle Decoration Circle Decoration

Want to dive deeper into Inimex Pharmaceuticals? Join now to access exclusive insights and find similar companies like this — powered by AI analytics.

Register Now